Compare Regeneron Pharmaceuticals Inc (REGN) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs DENTSPLY SIRONA Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while DENTSPLY SIRONA Inc trades at $10.68 (market cap $2.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 38.1× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| REGN | XRAY | |
|---|---|---|
Market Cap | $83.43B | $2.19B |
Sector | Health | Health |
52-Week High | $852.03 | $14.68 |
52-Week Low | $555.51 | $9.64 |
Enterprise Value | $78.14B | $4.26B |
Dividend Yield | 0.46% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing challenges amid a bearish technical signal. The company reported a Q2 2026 earnings beat but faces declining revenue and negative profitability, with a net income margin of -14.99%. Cash flow trends show volatility, and the debt-to-asset ratio has worsened to 42.88% in 2025. Recent news highlights margin pressure and a class-action lawsuit inquiry, clouding the near-term outlook despite some institutional buying interest.
The investment outlook is cautious. While the stock trades below the consensus price target of $12.50, persistent net losses, high debt, and competitive pressures pose significant risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited upside until the company demonstrates sustained operational improvement and revenue stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
